Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -184.76% | -27.22% | 107.44% | 21.24% | 207.45% |
| Total Depreciation and Amortization | 15.87% | 13.07% | 12.85% | 7.45% | 6.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.75% | -69.42% | 168.08% | -85.41% | -59.14% |
| Change in Net Operating Assets | 267.57% | -326.28% | -220.59% | -122.76% | -144.34% |
| Cash from Operations | -49.14% | -190.91% | -44.96% | -220.77% | 11.02% |
| Capital Expenditure | 5.18% | -472.41% | -150.58% | 48.83% | -70.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.24% | -100.03% | 12.50% | 25.00% | -16,090.22% |
| Cash from Investing | 92.74% | -102.48% | -143.33% | 48.51% | -4,379.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.97% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.97% | 100.00% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -157.41% | -500.00% | 120.00% | -14.29% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.51% | -205.94% | 58.98% | -108.45% | -337.10% |